(QDEL) Quidel - Ratings and Ratios

QuidelOrtho Corporation (NASDAQ: QDEL) is a leader in diagnostic testing solutions, operating across four distinct business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. The Labs division specializes in clinical chemistry and immunoassay instruments, providing critical data for patient health evaluation and disease management. Their Transfusion Medicine unit ensures compatibility and safety in blood transfusions and donor screening. The Point-of-Care segment offers rapid testing solutions for diverse healthcare settings, while Molecular Diagnostics focuses on innovative PCR and syndromic testing.

With a market cap of approximately $2.9 billion, QuidelOrtho is strategically positioned in the diagnostics industry, offering a broad range of testing solutions. Their products are distributed directly and through a global network, reaching physician offices, hospitals, and clinical laboratories. This extensive distribution underscores their commitment to accessibility and reliability in healthcare diagnostics.

QuidelOrthos financials, including a forward P/E of 17.27 and P/S of 1.04, highlight their potential for growth and profitability. Their global presence in North America, Europe, and other regions further solidifies their market reach. Established in 1979 and headquartered in San Diego, QuidelOrtho continues to innovate, making it a notable player in the diagnostics sector.